marijuana use in teens – KPBS” style=”width:100%;max-height:420px;object-fit:cover;border-radius:8px;display:block;” />#82 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
I don’t see a summary provided in your request. Please share the article summary so I can write the 2-3 sentences explaining its clinical relevance.
# Cannabis Use in Adolescents: Clinical Concerns Recent scientific evidence continues to highlight neurodevelopmental risks associated with cannabis use during adolescence, a period when the brain undergoes critical maturation of prefrontal and limbic structures. Studies demonstrate that teen cannabis users face increased risks for cognitive impairment, psychiatric symptoms including psychosis in vulnerable individuals, and long-term impacts on educational and occupational outcomes. These findings underscore the importance of clinicians screening adolescent patients for cannabis use and counseling about developmental vulnerability, particularly given the increased potency of modern cannabis products and the normalization of use in many communities. Healthcare providers should be aware that adolescent brains show differential susceptibility to cannabis-induced harm compared to adult users, and that early intervention during this critical window may mitigate long-term consequences. Parents and educators also need evidence-based information to support prevention and early identification efforts. Clinicians should incorporate cannabis risk assessment and education into routine adolescent visits, particularly for patients with psychiatric risk factors or family history of substance use disorders.
💭 While epidemiological concerns about adolescent cannabis use are warranted—particularly regarding potential impacts on neurodevelopment, academic outcomes, and mental health—clinicians should recognize that media coverage often conflates correlation with causation and may overstate effect sizes compared to peer-reviewed literature. The relationship between teen cannabis exposure and long-term outcomes is complex, confounded by factors including genetic predisposition to psychiatric illness, concurrent polysubstance use, socioeconomic stress, and pre-existing developmental vulnerabilities that may drive both cannabis initiation and adverse outcomes. Age at initiation, frequency of use, product type (especially high-THC formulations), and individual neurobiological factors all substantially modify risk, yet population-level warnings rarely capture this heterogeneity. When counseling adolescent patients and families, clinicians can acknowledge legitimate developmental concerns grounded in neuroscience while avoiding stigmatizing messaging, emphasizing that the evidence-based
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
